↓ Skip to main content

A phase IA dose-escalation study of PHI-101, a new checkpoint kinase 2 inhibitor, for platinum-resistant recurrent ovarian cancer

Overview of attention for article published in BMC Cancer, January 2022
Altmetric Badge

Mentioned by

twitter
1 tweeter

Readers on

mendeley
3 Mendeley